Abstract
ObjectivesLong-term safety and efficacy of adalimumab among patients with juvenile idiopathic arthritis (JIA) was evaluated through 6 years of treatment.MethodsChildren aged 4–17 years with polyarticular JIA were enrolled in a...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have